Changes in the levels of factor VIII and von Willebrand factor in the puerperium.
Summary of "Changes in the levels of factor VIII and von Willebrand factor in the puerperium."
Summary.  To determine changes in Factor VIII (FVIII) and von Willebrand Factor (VWF) in the first 3 days of the puerperium. A prospective study assessing FVIII clotting activity, VWF activity and antigen levels in 95 women (with singleton uncomplicated pregnancies) during labour and on days 1, 2 and 3 of the puerperium. There were no significant differences in FVIII,
VWF:
Ag and
VWF:
CB on days 1 and 2 of the puerperium compared with levels during labour. There was a significant decrease in
VWF:
Ag (P = 0.009) and
VWF:
CB (P = 0.04) on day 3. Age, ethnicity, duration of labour and mode of delivery did not have any significant effect on the changes in FVIII and VWF levels. The pregnancy induced increase in FVIII and VWF is maintained in the first 48 h after delivery. VWF levels start to decline on day 3 postdelivery.
Affiliation
Department of Obstetrics and Gynaecology, Royal Free Hospital, London; Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK.
Journal Details
This article was published in the following journal.
Name: Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21951573
- DOI: http://dx.doi.org/10.1111/j.1365-2516.2011.02625.x
Medical and Biotech [MESH] Definitions
Factor Viii
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
Von Willebrand Factor
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
Factor Viiia
Activated form of factor VIII. The B-domain of factor VIII is proteolytically cleaved by thrombin to form factor VIIIa. Factor VIIIa exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor X by factor IXa. Factor VIIIa is similar in structure and generation to factor Va.
Deamino Arginine Vasopressin
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
Von Willebrand Diseases
Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.
PubMed Articles
Principles of care for the diagnosis and treatment of von Willebrand disease.
Von Willebrand disease is a common autosomal inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor, a multi-adhesive protein that binds platelets to expose...
Analysis of the products of cryoprecipitation: RiCoF is deficient in cryosupernatant plasma.
INTRODUCTION: Cryoprecipitate and its byproduct, cryosupernatant plasma (CSP) have been used to treat specific medical diseases such as hemophilia, von Willebrand disease and thrombotic thrombocytopen...
Case of acquired hemophilia with factor VIII inhibitor in a mother and newborn.
We report a mother and newborn in the puerperium with hemorrhage secondary to factor VIII inhibitor. A 31-year-old gravida 1 para 1 delivered at a local clinic with a massive postpartum hemorrhage. Th...
Background: Protamine sulfate is the antidote for heparin, but in excess it exerts weak anticoagulation. Methods: We evaluated the effects of increasing protamine concentrations (0 to 24 mug/mL) on pr...
Membrane binding properties of the factor VIII C2 domain.
Factor VIII functions as a cofactor for factor IXa in a membrane-bound enzyme complex. Membrane binding accelerates activity of the factor VIIIa-factor IXa complex approximately 100,000-fold and the m...
Clinical Trials
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Will...
The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic para...
The objectives of this study are to evaluate the immediate tolerability and safety of rVWF:rFVIII in subjects with Type 3 Von Willebrand Disease after administration of various dosages of...
Trial to Evaluate the Efficacy and Safety of a New Formulation of Kogenate for Hemophilia A
Part A of the study will compare the pharmacokinetics (bioequivalence) of a new formulation of Kogenate (recombinant Factor VIII) with the current formulation. Part B will evaluate the sa...
Factor XI Levels in Acute Ischemic Stroke
The purpose of this study is to evaluate the utility of measuring coagulation factor activities in the setting of acute ischemic stroke, as potential markers of inherited thrombotic risk....
